Patents by Inventor Changyong QIU

Changyong QIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF
    Publication number: 20240352053
    Abstract: The present invention relates to salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms.
    Type: Application
    Filed: August 19, 2022
    Publication date: October 24, 2024
    Applicant: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Liang CHEN, Changyong QIU, Xiangyong LIU, Jian TANG, Lieming DING, Jiabing WANG
  • EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF
    Publication number: 20230133169
    Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 4, 2023
    Applicant: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Xiangyong LIU, Changyong QIU, Guolong DU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Lieming DING, Jiabing WANG
  • QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF
    Publication number: 20230131025
    Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.
    Type: Application
    Filed: February 8, 2021
    Publication date: April 27, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xiangyong LIU, Changyong QIU, Mengqiang LIU, Xiaodong SONG, Qichao SHEN, Guolong DU, Haitong SHENG, Lieming DING, Jiabing WANG
  • EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR
    Publication number: 20220402948
    Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 22, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Haitong SHENG, Mengqiang LIU, Qichao SHEN, Guolong DU, Xiaodong SONG, Lieming DING, Jiabing WANG
  • EGFR Inhibitor, Composition, and Preparation Method Therefor
    Publication number: 20220259235
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 23, 2020
    Publication date: August 18, 2022
    Inventors: Xiangyong Liu, Changyong Qiu, Qichao Shen, Mengqiang Liu, Haitong Sheng, Xiaodong Song, Guolong Du, Jiabing Wang, Lieming Ding
  • EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF
    Publication number: 20220227796
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 21, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Guolong DU, Jiabing WANG, Lieming DING